CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 66 enrolled
Drug / intervention
Neurexan® +1 moredrug
Likely dose
Neurexan® 0.6 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01703819
NCT01703819Phase 2Completed
CompareCT.gov

Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting - an Explorative Double-blind Study in Healthy Probands

Biologische Heilmittel Heel GmbH·interventional·Posted Oct 11, 2012·Updated Feb 11, 2015

In Brief

A Phase 2 clinical trial evaluating Neurexan® and Placebo for Acute Stress Reaction. Completed, enrolled 66 participants across 2 sites.

Detailed Summary

The purpose of this study is to evaluate the efficacy of acutely dosed Neurexan using an experimental stress test called the Trier Social Stress Test

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Stress Reaction
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedOct 11, 2012
Enrollment StartOct 1, 2012
Primary CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.7 years ago

Interventions

Neurexan®drug

0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes

Placeboother

6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes